A Big Win for Diabetic Kidney Disease: CREDENCE.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 31067448.
- Also identified by DOI 10.1016/j.cmet.2019.04.011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Diabetic kidney disease (DKD), a major cause of morbidity, mortality, and economic hardship globally, is on the rise. The results of the recently reported CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial have ushered in hope and optimism for the treatment of DKD.
Medical subject headings
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies